Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Short term Debt (2020 - 2023)

Zevra Therapeutics (ZVRA) has disclosed Short term Debt for 3 consecutive years, with $37.7 million as the latest value for Q4 2023.

  • For the quarter ending Q4 2023, Short term Debt changed N/A year-over-year to $37.7 million, compared with a TTM value of $37.7 million through Dec 2023, changed N/A, and an annual FY2023 reading of $37.7 million, changed N/A over the prior year.
  • Short term Debt was $37.7 million for Q4 2023 at Zevra Therapeutics, up from $683000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $37.7 million in Q4 2023 and bottomed at $390000.0 in Q4 2020.
  • Average Short term Debt over 3 years is $12.9 million, with a median of $683000.0 recorded in 2021.